Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Group 1: Allegations and Class Period - The class period for the allegations spans from June 22, 2023, to June 24, 2025 [3]. - Allegations include that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, which is a prescription gene therapy for Duchenne muscular dystrophy [3]. - Specific claims include significant safety risks associated with ELEVIDYS, failure of trial protocols to detect severe side effects, and the potential halting of recruitment and dosing in trials due to adverse events [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 25, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices [5]. - The firm emphasizes the importance of responsible business practices and seeks recovery for investors affected by misleading statements that inflated stock prices [5].

Group 1 - The U.S. FDA has placed Sarepta Therapeutics Inc.'s SRPT investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) on clinical hold due to serious safety concerns, including three patient deaths potentially linked to the products [1] - The FDA has requested Sarepta to voluntarily halt all shipments of Elevidys, the company's approved gene therapy, but Sarepta has refused this request [2] - Analysts from Needham have downgraded Sarepta from Hold to Underperform, expressing concerns that the FDA's feedback puts Elevidys' future in jeopardy and may challenge the company's ability to meet its 2027 debt obligations [3][4] Group 2 - William Blair views the FDA's announcement as a worst-case scenario for Sarepta, potentially affecting patient interest in Elevidys and indicating a fractured relationship with the FDA [5] - William Blair maintains a Market Perform rating for Sarepta, suggesting that Elevidys will not be formally withdrawn from the market, but anticipates a delayed BLA submission for SRP-9003 and lower commercial adoption of Elevidys [6] - Other analysts have also downgraded Sarepta, with Mizuho lowering the price forecast from $40 to $14, and Piper Sandler reducing it from $32 to $18 [7]

Regulatory Action - Sarepta Therapeutics rejects FDA's request to halt shipments of its muscular dystrophy drug [1]

Core Insights - Shares of Sarepta Therapeutics (SRPT) fell 35.9% following the death of a patient in a trial for its gene therapy SRP-9004, which is aimed at treating limb-girdle muscular dystrophy (LGMD) Type 2D [1][9] - This incident marks the third patient death linked to Sarepta's gene therapies, with previous deaths occurring in non-ambulatory patients treated with Elevidys for Duchenne muscular dystrophy (DMD) [2][9] - The FDA has placed all of Sarepta's clinical studies for LGMD on hold and requested a halt to Elevidys shipments, which the company has refused, citing safety data [5][6][9] Company Developments - Sarepta has suspended Elevidys dosing for non-ambulatory patients and is considering enhanced immunosuppression to improve safety [3] - The company has lowered its net product revenue guidance for full-year 2025 to $2.3-$2.6 billion from $2.9-$3.1 billion due to safety concerns affecting drug uptake [4] - Sarepta announced a restructuring plan to cut 36% of its workforce, aiming for annual savings of $400 million by 2026 [13][15] Regulatory Actions - The FDA has revoked Sarepta's AAVrh74 platform technology designation, citing insufficient evidence to support its safety for multiple drugs [10] - The agency continues to assess risks associated with gene therapies based on this platform, including severe liver complications [10] Product Information - Elevidys is the first and only one-time gene therapy for DMD in the U.S., approved for individuals aged four years and older [11] - The therapy has received full approval for ambulatory DMD patients but only accelerated approval for non-ambulatory patients [11] Financial Impact - Sarepta's sales from Elevidys accounted for over half of its revenue in Q1 2025, and the recent safety concerns are expected to severely impact sales in the latter half of the year [4] - The company anticipates more than $100 million in cost savings this year despite incurring one-time charges of up to $37 million [15]

Welcome back to Squawk on the Street. Healthc care you might know the worst performing sector of the year so far. Just one of just three still in the red since January after we got weakness in one part of the market.The health insurers names like Centine, UNH, Molina, Eleance all have had bad news last couple of weeks. Down double digits on the year and more than cut in half off of their 52- week highs. It's been a non-stop stream of bad news from almost all of those names.Yeah, brutal. Also pharma as well. ...

Group 1 - Sarepta Therapeutics' stock has dropped over 35% to below $13 after rejecting the FDA's request to halt shipments of Elevidys, following a third death linked to the gene therapy [2][3] - Elevidys accounts for 43% of Sarepta's total revenues and has traditional approval since June 2024 for ambulatory patients, making any regulatory challenges a significant threat to the company's existence [3] - FDA Commissioner Marty Makary's comments indicate a potential forced withdrawal of Elevidys if voluntary compliance is not achieved, raising concerns about the adequacy of recent $400 million restructuring cost savings against potential revenue losses [4] Group 2 - Sarepta's confrontational stance towards federal regulators is creating unprecedented uncertainty in the biotech sector, highlighting poor risk management at a critical regulatory juncture [5] - The situation emphasizes the inherent risks of investing in single stocks, suggesting that professionally managed portfolios may offer a more stable investment approach [5][6] - Regulatory risk is part of a broader risk assessment framework, with the Trefis High Quality Portfolio demonstrating better returns with less risk compared to the S&P 500 over the past four years [6]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1] Group 1: Allegations - The complaint alleges that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, which posed significant safety risks to patients [1] - It is claimed that the trial protocols for ELEVIDYS failed to detect severe side effects, leading to potential regulatory scrutiny and halting of recruitment and dosing in trials [1] - The severity of adverse events from ELEVIDYS treatment is said to have misled investors regarding the therapy's approval prospects and overall safety [1] Group 2: Class Action Details - The class period for the lawsuit is defined as June 22, 2023, to June 24, 2025, and shareholders are encouraged to register for participation [2] - The deadline for shareholders to seek lead plaintiff status is August 25, 2025, with no cost or obligation to participate in the case [2] Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics due to allegations of violations of federal securities laws related to misleading statements about the safety of its product ELEVIDYS [3][5]. Company Overview - Sarepta Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare diseases, particularly those related to genetic disorders [3]. Legal Proceedings - A federal securities class action has been filed against Sarepta, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][12]. - The complaint alleges that Sarepta and its executives made false or misleading statements regarding the safety of ELEVIDYS, which posed significant risks to patients [5]. Product Safety Issues - On March 18, 2025, Sarepta reported a patient death following treatment with ELEVIDYS, leading to a stock price drop of $27.81 per share, or 27.44%, closing at $73.54 [6]. - Following regulatory scrutiny, Sarepta halted recruitment and dosing in some ELEVIDYS clinical studies on April 4, 2025, resulting in a further stock price decline of $4.18 per share, or 7.13%, to close at $54.43 [7][8]. - A second patient death due to acute liver failure was disclosed on June 15, 2025, prompting Sarepta to suspend shipments of ELEVIDYS for non-ambulatory patients and pause dosing in one clinical study, causing a significant stock price drop of $15.24 per share, or 42.12%, to close at $20.91 [9][10]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into the risk of acute liver failure associated with ELEVIDYS, leading to an additional stock price decline of $1.52 per share, or 8.01%, to close at $17.46 [10][11]. Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in Sarepta to contact them for discussions about their legal rights and options [1][13].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2]. - Investors have until August 25, 2025, to request to lead the case [2]. Group 2: Product and Allegations - Sarepta is focused on developing treatments for rare diseases, with Elevidys being its key product for Duchenne muscular dystrophy [3]. - The complaint alleges that Sarepta misrepresented the safety profile of Elevidys, claiming its benefits outweighed risks, while it is linked to fatal acute liver failure in some patients [3]. Group 3: Stock Performance and Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third death related to Elevidys was reported on July 17, 2025, causing the stock to fall more than 40% on July 18, 2025 [5].

美国食品药品管理局（FDA）要求 Sarepta Therapeutics Inc.（SRPT）暂停分销Elevidys。 ...